Search results for "myocardial infarction."

showing 10 items of 1011 documents

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R …

2019

The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 &plusmn

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinlcsh:Medicine030204 cardiovascular system & hematologyKoronare HerzkrankheitRevascularizationAbsorbable implantsCoronary artery diseaseArticleCoronary artery diseasedrug eluting stents03 medical and health sciences0302 clinical medicineDrug-eluting StentMedizinische Fakultätstent bioresorbableMedicine030212 general & internal medicineMyocardial infarctionddc:610Drug-eluting stentsTissue scaffoldsEverolimusbusiness.industrylcsh:RStentGeneral Medicinemedicine.diseaseThrombosisSurgeryConventional PCIbusinessDDC 610 / Medicine & healthcoronary artery diseasemedicine.drugJournal of Clinical Medicine
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all

2020

: Periodontal disease is conventionally defined as an inflammatory condition affecting the tissues surrounding and supporting the teeth (i.e. gum and periodontium). Recent statistics show that the prevalence of this condition is continuously growing worldwide, thus raising severe healthcare concerns, not only for local problems emerging from poor oral health, but also for the potential risk of developing systemic complications. Therefore, this article aims to provide an update on the intriguing association between periodontitis, coronary heart disease (CHD) and/or myocardial infarction (MI). Taken together, the available published information seems to support the existence of a significant …

medicine.medical_specialtyPeriodontitis coronary heart disease myocardial infarctionCoronary Artery Disease030204 cardiovascular system & hematologyOverweightCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineAnimalsHumansMyocardial infarctionEndothelial dysfunctioncoronary heart diseasePeriodontitisPeriodontitisbusiness.industryHematologyGeneral MedicinePeriodontiummedicine.diseaseCoronary heart diseaseTreatment Outcomemyocardial infarctionmedicine.symptomHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness030215 immunology
researchProduct

Causal linear parametric model for baroreflex gain assessment in patients with recent myocardial infarction

2001

Spectral and cross-spectral analysis of R-R interval and systolic arterial pressure (SAP) spontaneous fluctuations have been proposed for noninvasive evaluation of baroreflex sensitivity (BRS). However, results are not in good agreement with clinical measurements. In this study, a bivariate parametric autoregressive model with exogenous input (ARXAR model), able to divide the R-R variability into SAP-related and -unrelated parts, was used to quantify the gain (αARXAR) of the baroreflex regulatory mechanism. For performance assessing, two traditional noninvasive methods based on frequency domain analysis [spectral, baroreflex gain by autogressive model (αAR); cross-spectral, baroreflex gain…

medicine.medical_specialtyPhysiologySystoleEntropyRR intervalMyocardial InfarctionHemodynamicsBlood PressureBaroreflexAutoregressive modelSpectral analysiElectrocardiographyPhenylephrineHeart RateInternal medicinePhysiology (medical)MedicineHumansVasoconstrictor AgentsIn patientAnalysis of VarianceModels Statisticalbusiness.industryModels CardiovascularBaroreflexMiddle AgedR-R-SAP transfer functionSurgeryBlood pressureBaroreflex sensitivityParametric modelCardiologySystolic arterial pressureRegression AnalysisCardiology and Cardiovascular MedicinebusinessRecent myocardial infarction
researchProduct

P674Metabolic deregulation in myocardial infarction is mediated by PGC-1 alpha pathway

2014

Purpose: In the context of myocardial infarction (MI) the availability of metabolites is clearly restricted, therefore a fuel metabolic shifts takes place. Previous studies have indicated that peroxisome proliferator activated receptor co-activator alpha (PGC-1α) pathway is a crucial regulator of cardiac metabolism in response to cardiac stress. Here we address the role of PGC-1α in regulating metabolic changes of MI. Methods: We studied a group of 12 common swine in which anterior MI was induced by means of angioplasty balloon inflation. A series of 6 swine were sacrificed at 48h post-infarction (acute infarction group) and another series of 6 swine were sacrificed at 3 weeks (chronic infa…

medicine.medical_specialtyPhysiologybusiness.industryInfarctionContext (language use)MetabolismCarbohydrate metabolismmedicine.diseaseFold changeReperfusion therapyEndocrinologyBiochemistryPhysiology (medical)Internal medicineKetone bodiesMedicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessCardiovascular Research
researchProduct

Platelet Function Changes in Acute Myocardial Infarction

1984

Whether the thrombotic component of myocardial infarction is primary or secondary in a given patient, platelet function alterations can influence many mechanisms — operating at the microenvi-ronmental level — from which it depends if the thrombotic lesion grows or sends platelet emboli to the smaller myocardial vessels.

medicine.medical_specialtyPlatelet aggregationbusiness.industrymedicine.diseaseLesionInternal medicinecardiovascular systemmedicineCardiologyPlateletcardiovascular diseasesSpontaneous platelet aggregationMyocardial infarctionmedicine.symptombusiness
researchProduct

Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Scor…

2021

Abstract Objectives We sought to evaluate clinical outcomes in patients treated with the drug-eluting stent ihtDEStiny BD. Background The ihtDEStiny BD stent is a metallic sirolimus eluting stent with a biodegradable polymer with both drug and polymer coating the abluminal surface of the stent and balloon. Methods In this study, the clinical outcomes of a multicenter prospective registry of patients treated with this stent (DEStiny group) were analyzed and compared with those of a control group of patients treated with durable polymer everolimus or zotarolimus eluting stents (CONTROL group) paired by propensity score matching . Primary outcome was the target vessel failure (TVF) at 12 month…

medicine.medical_specialtyPolymersmedicine.medical_treatment030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionAbsorbable ImplantsmedicineClinical endpointHumansZotarolimus030212 general & internal medicineMyocardial infarctionEverolimusPropensity ScoreSirolimusEverolimusbusiness.industryStentDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular revascularization medicine : including molecular interventions
researchProduct

0128: CHA2DS2-VASc score estimates in-hospital mortality beyond GRACE score after acute myocardial infarction

2016

International audience; Background and aimsCHA2DS2VASc score have recently been suggested to predict death in patients with Atrial Fibrillation (AF). In acute myocardial infarction (AMI), silent AF is more common than symptomatic AF and associated with poor prognosis. In patients with AMI, we aimed to assess the distribution of CHA2DS2VASc score in patients with silent or symptomatic AF and the association of the score with mortality.Methods849 consecutive AMI were prospectively analyzed by continuous ECG monitoring (CEM) 30 sec. Symptomatic AF was defined as any AF occurring on ECG during the hospital stay, resulting in clinical symptoms or need for urgent cardioversion. The population was…

medicine.medical_specialtyPoor prognosismedicine.medical_treatment030204 cardiovascular system & hematologyCardioversion03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineAtrial FibrillationmedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionFramingham Risk ScoreIn hospital mortalitybusiness.industryAtrial fibrillation[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthmyocardial infarctionCHA2DS2–VASc scoreCardiologyCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Aplicación de The Community Assessment Risk Screen en centros de atención primaria del Sistema Sanitario Valenciano

2014

ResumenObjetivoAplicar la herramienta The Community Assessment Risk Screen (CARS) para detectar pacientes mayores con riesgo de reingreso hospitalario y estudiar la viabilidad de su inclusión en los sistemas de información sanitaria.DiseñoEstudio de cohortes retrospectivo.EmplazamientoDepartamentos de salud 6, 10 y 11 de la Comunidad Valenciana.ParticipantesPacientes de 65años o más atendidos en diciembre de 2008 en 6 centros de salud. La muestra fue de 500 pacientes (error muestral=±4,37%, fracción de muestreo=1/307).MedicionesInstrumento CARS formado por 3ítems: diagnósticos (enfermedades cardiacas, diabetes, infarto de miocardio, ictus, EPOC, cáncer), número de fármacos prescritos e ingr…

medicine.medical_specialtyPopulationPrimary careManagement of chronic patientsHealth informaticsReingreso hospitalarioElderlyMedicineMayoresGestión pacientes crónicosMyocardial infarctioneducationStrokePrimary CareMedicine(all)lcsh:R5-920COPDeducation.field_of_studyHospital readmissionbusiness.industryRetrospective cohort studyGeneral MedicineHospital readmissionmedicine.diseaseAtención primariaCommunity Assessment Risk ScreenEmergency medicinelcsh:Medicine (General)Family PracticebusinessAtención Primaria
researchProduct

0139 : Extrahospital troponin measurement before admission for a ST segment elevation myocardial infarction

2016

International audience; Background and aimEarly and reliable triage of patients is of major importance to promote rapid and appropriate treatments of patients with ST segment elevation myocardial infarction (STEMI). Extrahospital troponin measurement is used in primary care setting to help the identification of patients with suspected MI. From a regional survey (RICO), we aimed to investigate the frequence and hospital prognosis of STEMI patients with prehospital troponin (PT) measurement.Methods and resultsProspective study on 799 consecutive patients with STEMI included in RICO from March 2013 – 31 may 2015. Among the 799 patients, 38(5%) were identified with PT, from source files and pat…

medicine.medical_specialtyPrimary care030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin (PT) measurementmedicineTroponin measurementST segment030212 general & internal medicineMyocardial infarctionSymptom onsetSTEMI patientsProspective cohort studyIntensive care medicineST segment elevation myocardial infarctionbiologybusiness.industrymedicine.diseaseTroponinTriage3. Good health[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Emergency medicinebiology.protein[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]businessCardiology and Cardiovascular MedicineArchives of Cardiovascular Diseases Supplements
researchProduct